In contrast to the positive influence of tumor ICAM-1 expression on T-cell activity, tumor cell PD-L1 and PD-L2 expression reduce T-cell driven anti-tumor cytotoxicity by binding to the PD-1 immune checkpoint receptor expressed on the surface of T-cells [31–33]. Here, ICAM1 is linked to neoplasm.